The Technical Analyst
Urogen Pharma Ltd [URGN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Urogen Pharma Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.73% $14.24
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 485.90 mill |
| EPS: | -3.55 |
| P/E: | -4.01 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 34.12 mill |
| Avg Daily Volume: | 0.377 mill |
| RATING 2024-04-17 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.01 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.68x |
| Company: PE -4.01 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 13.02 - 15.46 ( +/- 8.57%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-18 | Schoenberg Mark | Sell | 12 000 | Ordinary Shares |
| 2024-01-31 | Kim Dong | Buy | 3 333 | Ordinary Shares |
| 2022-03-25 | Kim Dong | Buy | 20 000 | Stock Option (right to buy) |
| 2024-02-01 | Smith Jason Drew | Sell | 3 328 | Ordinary Shares |
| 2024-02-01 | Smith Jason Drew | Sell | 1 248 | Ordinary Shares |
| INSIDER POWER |
|---|
| 58.62 |
| Last 96 transactions |
| Buy: 1 308 776 | Sell: 407 960 |
Forecast:
16:00 - $14.24
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $14.24
Forecast 2: 16:00 - $14.24
Forecast 3: 16:00 - $14.24
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $14.24 (-1.73% ) |
| Volume | 0.170 mill |
| Avg. Vol. | 0.377 mill |
| % of Avg. Vol | 44.96 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For URGN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $18.48 | N/A | Active |
|---|
URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Last 10 Buy Signals
Latest Press Releases
2024-04-17 12:02:00 - Press Release
Urogen Announces New Data Presentations At The American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits Of Our Portfolio For Urothelial Cancers
Princeton, n.j.--(business wire)--urogen pharma ltd. (nasdaq: urgn), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on investigational drug ugn-102 (mitomycin) and jelmyto and will be presented at the american urological association (aua) 2024 annual meeting being held in san antonio, texas from may 3 – 6. “we are proud that the aua selected the atlas post-hoc analysis as a podium pres.
2024-04-15 08:00:00 - Press Release
Urogen Announces Fda Acceptance Of Investigational New Drug Application For Ugn-103, A Next Generation Mitomycin-based Formulation For Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
Princeton, n.j.--(business wire)--urogen pharma ltd. (nasdaq: urgn), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the u.s. food and drug administration (fda) accepted the company's investigational new drug (ind) application for ugn-103, a next-generation novel mitomycin-based formulation for low-grade intermediate-risk non-muscle invasive bladder cancer (lg-ir-nmibc). the ugn-103 formulation uses uroge.
2024-04-03 08:00:00 - Press Release
Urogen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
Princeton, n.j.--(business wire)--urogen pharma ltd. (nasdaq: urgn), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has filed a lawsuit in the u.s. district court for the district of delaware against teva pharmaceuticals, inc., teva pharmaceuticals usa, inc., and teva pharmaceutical industries, ltd., alleging infringement of u.s. patent numbers 9,040,074 (“the '074 patent”) and 9,950,069 (“the '0.
2024-03-14 08:00:00 - Press Release
Urogen Pharma Delivers Double Digit Jelmyto® Growth And Prepares For The Next Phase Of The Company With On Track Rolling Submission Of Ugn-102
Princeton, n.j.--(business wire)--urogen pharma ltd. (nasdaq: urgn), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the fourth quarter and full year ended december 31, 2023, and provided an overview of recent developments. “in 2023, urogen achieved important operational and clinical milestones, setting us up for further success in the coming years,” said liz barrett, president.
2024-03-08 08:00:00 - Press Release
Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Princeton, n.j.--(business wire)--urogen pharma ltd. (nasdaq: urgn), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“rsus”) to 12 new employees in connection with their employment with urogen. these new team members will support the ongoing commercialization of jelmyto® (mitomycin) for pyelocalyceal solution, urogen's first approved product, and the c.
Latest News
2024-03-14 20:13:09 - Seeking Alpha
UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript
2024-03-14 10:10:14 - Zacks Investment Research
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $1.22 per share a year ago.
2023-11-14 14:59:09 - Seeking Alpha
Urogen Pharma Ltd (URGN) Q3 2023 Earnings Call Transcript
2023-08-18 14:49:14 - Zacks Investment Research
UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why
This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the candidate is expected next year.
2023-08-10 11:30:58 - Zacks Investment Research
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet
The consensus price target hints at an 89.6% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2023-08-10 10:46:52 - Zacks Investment Research
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.18 per share a year ago.
2023-07-28 13:41:19 - The Motley Fool
Why Shares of UroGen Pharma Jumped Friday
UroGen also announced a $120 million private placement to raise funds. The company said it could have its second marketed product as early as next year.
2023-03-16 10:42:41 - Zacks Investment Research
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-03-01 16:00:00 - Business Wire
UroGen Pharma to Present at Upcoming Investor Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in March: Cowen 43rd Annual Health Care Conference — March 7-9, 2023 Panel Presentation Date: Tuesday, March 7th from 12:50-1:50pm ET Webcast Link: https://wsw.
2023-02-08 04:04:38 - Seeking Alpha
UroGen: Struggling With Revenue And With Cash Runway
